Guidelines

New guidelines address primary cutaneous T-cell lymphoproliferative disorders

Publish date: April 14, 2014

 

AT THE NCCN ANNUAL CONFERENCE

Dr. Zelenetz is a scientific adviser for Cancer Genetics Inc. and Gilead and has received consulting fees, honoraria, and/or grant or other research support from Celgene Corp., Cephalon Inc., Genentech Inc., GlaxoSmithKline, Roche Laboratories Inc., sanofi-aventis U.S., and Seattle Genetics Inc.

Pages

Recommended Reading

In situ melanoma high risk for subsequent diagnosis
MDedge Dermatology
Melanomas were less invasive at diagnosis in patients with established dermatologist
MDedge Dermatology
Immunotherapy for melanoma progresses with some interesting response patterns
MDedge Dermatology
New study supports imiquimod for lentigo maligna
MDedge Dermatology
What’s old is new again for actinic keratoses treatment
MDedge Dermatology
Substantial delay seen in melanoma surgery for Medicare patients
MDedge Dermatology
Increased Risk for Melanoma in Men With Prostate Cancer: Implications for Clinical Practice?
MDedge Dermatology
House panel chides FDA for inaction on sunscreens
MDedge Dermatology
First-Degree Relatives of Melanoma Patients May Experience Counterphobia
MDedge Dermatology
Monoclonal antibody pinpoints BRAF status in melanoma
MDedge Dermatology